tiprankstipranks
Syntara Limited Faces Major Revenue Drop and Losses
Company Announcements

Syntara Limited Faces Major Revenue Drop and Losses

Pharmaxis Ltd (AU:SNT) has released an update.

Don't Miss our Black Friday Offers:

Syntara Limited reported a sharp decline in revenues, down 66.9% to $6,399,000, alongside a 33.3% increase in losses at $15,142,000 for the fiscal year ended 30 June 2024. There were no dividends issued, and the company’s net tangible assets per share plummeted from 1.23 cents to 0.38 cents. Additionally, the company has shed its non-operating subsidiaries as part of the Mannitol Business Unit sale.

For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskSyntara Limited to Present Promising Cancer Trial Results
TipRanks Australian Auto-Generated NewsdeskPharmaxis Ltd Highlights Product Pipeline and Risks
TipRanks Australian Auto-Generated NewsdeskSyntara Limited Advances Drug Trials and Financial Strategy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App